The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

Sponsor

University of California, San Francisco (Other)

Overall Status

Recruiting

CT.gov ID

NCT06152653

Collaborator

National Heart, Lung, and Blood Institute (NHLBI) (NIH)

Enrollment

Location

Arms

Anticipated Duration (Months)

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD).

The main questions it aims to answer are:

Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on mucus plug burden in the lungs than delivery of NAC without positive pressure.
Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on lung function than delivery of NAC without positive pressure.

Participants will be assigned (in a single blind design) to the NAC via jet nebulizer group or the NAC via Hillrom-Volara nebulizer group. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments of a 10% NAC (3 mL) and 2.5 mg albuterol (0.5mL) inhalation solution separated by 4 hours, via the nebulization method specific to their group.

Condition or Disease	Intervention/Treatment	Phase
Asthma COPD	Drug: n-acetylcystine (NAC)+ albuterol Device: Hillrom-Volara System	Phase 4

Detailed Description

The optimal method for delivering aerosolized N-acetyl cysteine (NAC, Mucomyst) to the airways for the purpose of lysing mucus plugs is not established. The challenge is to ensure that the NAC aerosol penetrates the mucus plug to lyse it. We hypothesize that increasing the inspiratory pressure during aerosol inhalation will improve mixing of NAC with plugs and increase the chance of lysis within the time that the NAC liquid medication "dwells" in the plugged airway segment. Usual nebulizer systems that generate aerosols for inhalation do not allow for application of pressure during inspiration, but the Volara system (from Hillrom) has this capability. Specifically, the Volara system combines continuous positive pressure during inspiration while the patient inhales aerosol medication, and the pressure will generate viscous fingers in the mucus plugs to aid lysis.

Recent published work from the Fahy lab has revealed that airway mucus plugs can be identified on low dose CT scans of the lungs and quantified using a bronchopulmonary segment based system to generate a measure that quantifies the mucus plug burden in the lung. This CT based mucus plug scoring system provides a predictive and monitoring biomarker for mucus plug pathology in the lungs of patients with asthma and COPD.

This is a single-blind phase 4 clinical trial designed to help determine the optimal method of delivery of aerosolized NAC to patients with mucus-associated lung disease (asthma and COPD). Subjects will be screened for evidence of mucus in their lungs as determined by CT imaging. Eligible participants will then be assigned to the NAC via jet nebulizer group or the NAC via Hillrom-Volara nebulizer group and complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments of a 10% NAC (3 mL) and 2.5 mg albuterol (0.5mL) inhalation solution separated by 4 hours, via the nebulization method specific to their group.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

20 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Participant)

Primary Purpose:

Treatment

Official Title:

The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC

Actual Study Start Date :

Nov 21, 2023

Anticipated Primary Completion Date :

Nov 21, 2027

Anticipated Study Completion Date :

Nov 21, 2027

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: NAC via jet nebulizer NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 10% NAC coadministered with albuterol and delivered via standard jet nebulizer. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments separated by 4 hours.	Drug: n-acetylcystine (NAC)+ albuterol NAC is a mucolytic drug and Albuterol is a bronchodilator. Other Names: Mucomyst NAC
Experimental: NAC via Hillrom-Volara NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 10% NAC coadministered with albuterol and delivered via the Hillrom-Volara system. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments separated by 4 hours.	Drug: n-acetylcystine (NAC)+ albuterol NAC is a mucolytic drug and Albuterol is a bronchodilator. Other Names: Mucomyst NAC Device: Hillrom-Volara System The Hillrom Volara System combine continuous positive expiratory pressure and nebulizer in one system. Other Names: Volara System

Arm

Intervention/Treatment

Active Comparator: NAC via jet nebulizer

NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 10% NAC coadministered with albuterol and delivered via standard jet nebulizer. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments separated by 4 hours.

Drug: n-acetylcystine (NAC)+ albuterol

NAC is a mucolytic drug and Albuterol is a bronchodilator.

Other Names:

Mucomyst

NAC

Experimental: NAC via Hillrom-Volara

NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 10% NAC coadministered with albuterol and delivered via the Hillrom-Volara system. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments separated by 4 hours.

Drug: n-acetylcystine (NAC)+ albuterol

NAC is a mucolytic drug and Albuterol is a bronchodilator.

Other Names:

Mucomyst

NAC

Device: Hillrom-Volara System

The Hillrom Volara System combine continuous positive expiratory pressure and nebulizer in one system.

Other Names:

Volara System

Outcome Measures

Primary Outcome Measures

Change in mucus plug score [1 week before treatment to 1 week post treatment, an average of 6 weeks]
The primary outcome is the % change in mucus plug score from 1 week before treatment to 1 week post treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 85 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Asthma Group:

Male or female between the ages of 18 to 85 at Visit 1
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Able to perform reproducible spirometry according to ATS criteria
Clinical history of asthma per patient report or medical record
Asthma requiring treatment with inhaled corticosteroids (ICS) or biologic therapy for 3 months or greater
CT mucus score ≥ 3 (done as part of screening)
There is no lower threshold on FEV1, which means the study will attempt to enroll all patients regardless of asthma severity. However, eligible participants will need to demonstrate ability to tolerate study treatment reflected by a post-treatment FEV1 ≥ 80% of pre- treatment, pre-bronchodilator FEV1. Participants who have a >20% drop in FEV1 after receiving any study treatment will be excluded from the study.
For participants with known mucus plugging on CT: no limit on FEV1;

For participants with unknown mucus plugging: FEV1<70% predicted

COPD Group:

Males or females between the ages 18 to 85 at the time of visit 1.
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
History of COPD per patient report or medical record and confirmed by an FEV1/FVC ratio of under 70%.
Current or former smoker with a history of at least 10 pack-years of smoking.
CT mucus score ≥ 3
There is no lower threshold on FEV1, which means the study will attempt to enroll all patients regardless of COPD severity. However, eligible participants will need to demonstrate ability to tolerate study treatment reflected by a post-treatment FEV1 ≥ 80% of pre- treatment, pre-bronchodilator FEV1. Participants who have a >20% drop in FEV1 after receiving any study treatment will be excluded from the study.
For participants with known mucus plugging on CT: no limit on FEV1; For participants with unknown mucus plugging: FEV1<50% predicted

Exclusion Criteria:

A history of medical disease, which in the opinion of the investigator may put the subject at extra risk from study-related procedures or because the disease may influence the results of the study.
Currently pregnant
URI in past 10 days